Objective: The aim of this study was to determine the impact of patient-prosthesis mismatch (PPM) after mitral valve replacement (MVR) on the late clinical outcome, evaluated from the referred value and measured mitral valve area in the echocardiograph. Patients and Method: The records of 212 patients who underwent MVR between 1995 and 2008 at Funabashi Municipal Medical Center, Japan were studied retrospectively. Exclusions were patients who had a repeat MVR or concomitant aortic valve surgery. Of 212 patients, 163 underwent the Doppler echocardiographic study more than 1 year after surgery. Primary endpoint was late survival, and secondary endpoint was major adverse cardiac event (MACE). The average follow-up period was 53.1 ± 100.8 months. The effective orifice area index (EOAI) was calculated using the referred effective orifice area (r-EOA) and measured effective orifice area (m-EOA). An EOAI smaller than 1.2 cm 2 /m 2 defined PPM. Results: For r-EOAI, 125 patients (group P) had PPM and 87patients (group N) did not. Between groups, there was a significant difference in the proportion of males (group P vs. N; 59% vs. 23%; P = 0.0001), postoperative NYHA class (1.02 ± 6.2 vs. 9.8 ± 1.6, P = 0.04), late mitral valve area (MVA) (2.50 ± 0.56 vs. 2.78 ± 0.60, P = 0.005), and peak transmitral pressure gradient (MPG) 11.9 ± 6.2 vs 9.8 ± 1.6, P = 0.04). However, there was no difference in late survival (P = 0.55) or incidence of a major cardiac adverse event (MACE) (P = 0.14). For m-EOAI, 17 patients (group P) had PPM and 146 patients (group N) did not. Between groups, there was a difference in the bioprosthetic valve (group P vs. N; 76% vs. 26%, P = 0.006) and mean MPG (5.2 ± 2.3 vs. 3.7 ± 1.8、P = 0.02). However, there was no difference in late survival (P = 0.99) and incidence of MACE (P = 0.86). The r-and m-EOAI were well correlated (correlation coefficient 0.46; 0.33-0.5) Conclusions: The PPM after MVR was not related to the late survival or the incidence of MACE based on both r-and m-EOAI. The patient group of PPM defined by r-EOAI tended to be male and that defined by m-EOAI tended to be bioprosthetic.
Introduction
The concept of prosthesis-patient mismatch (PPM) was first described in 1978 by Rahimtoola et al. 1, 2) PPM occurs when the in vivo effective orifice area of the prosthetic valve is less than the native healthy valve area. 3) Though many have reported a link between PPM after aortic valve replacement (AVR) and late left ventricular function, cardiac events or survival, some do not agree that the link exists. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] On the other hand, the focus of attention on PPM is its occurring after AVR instead of mitral valve replacement (MVR). Within the past 10 years, there has been greater interest in PPM after MVR. [15] [16] [17] [18] [19] [20] [21] For determining PPM, some investigators measured the actual effective orifice area index (EOAI), though others referred to reported EOAI values. 15, 16, 19) The objectives of this study were to determine the impact of PPM after MVR on late clinical outcome determined from the echocardiograph, utilizing measured EOAI (m-EOAI) or referred EOAI (r-EOAI) and to correlate m-EOAI and r-EOAI.
Patients and Methods
Between 1995 and 2005, the records of 234 patients who underwent their first MVR were analyzed for possible inclusion in the study. Patients without a repeat MVR or concomitant aortic valve surgery were excluded (22) and baseline demographic and clinical data in the records of those who could be included (212) were used. We obtained institutional approval, and patients gave their written consent for use of the data.
The patients had standard surgical procedures for cardiopulmonary bypass and mild systemic hypothermia through median sternotomy. Cardiac arrest was obtained with Young and GIK solution. The mechanical prosthesis was SJM (St. Jude Medical, St. Paul, MN, USA) and the bioprosthesis was Carpenter-Edwards PERIMOUNT (Edwards Life sciences, Irvine, CA, USA). Concomitant surgery such as MAZE or coronary bypass was performed when indicated.
Echocardiographic examination was performed more than one year after the surgery. The mitral valve area was measured by the pressure half time method. Peak and mean transmitral pressure gradients, diastolic left ventricle diameter (LVDd) and systolic left ventricle diameter (LVDs), trans-tricuspid valve pressure gradient, (used as the index for systemic pulmonary pressure), and ejection fraction (EF) were measured at that time. Detailed echocardiographical data were obtainable from the 163 patients.
The primary endpoint was late survival, and secondary endpoint was major adverse cardiac event (MACE). The patients had follow-up visits in the outpatient clinic, periodically through the years (4.5 ± 8.4 years), in which health records and echocardiographs were reviewed.
Stratification. The reference effective orifice area (EOA) for each prosthesis was determined from the pub- 
Stratified by the r-EOAI
Preoperative and perioperative variables are shown in Table 1 . Of 212 patients, 125 (58.9%) had PPM (group P), and 87 (41.0%) did not (group N). Males were more common in group P (59%) than in group N (23%) (P = 0.0001). Postoperative NYHA class was significantly lower in group P (1.02 ± 0.37) than in group N (1.16 ± 0.52) (P = 0.03). Late echocardiographic data and clinical outcomes are shown in Table 2 . Peak trans-mitral pressure gradient was higher in group P (11.9 ± 6.2) than in group N (9.8 ± 4.5) (P = 0.04). Fig. 1 shows the survival curve, and Fig. 2 , freedom from MACE (major adverse cardiac event) of the stratification. There was no significant difference in late survival (P = 0.55) or freedom from MACE (P = 0.14)
Stratified by the m-EOAI
Preoperative and perioperative variables are shown in Table 3 . Of 163 patients, 17 (10.4%) had PPM (group P), and 146 (89.6%) did not (group N). perioperatively, the percentage of bioprosthetic valve was significantly higher in group P (76%) than in group N (26%) (P = 0.0006). Late echocardiographic data and clinical outcome were shown in Table 4 . mean trans-mitral pressure gradient was higher in group P (5.2 ± 2.3) than in group N (3.7 ± 1.8) (P = 0.02). Figure 3 and Figure 4 shows the survival curve, and freedom from MACE (major adverse cardiac event) of this stratification. There was no significant difference in late survival (P = 0.99) or freedom from MACE (P = 0.86) Figure 5 shows the correlation between r-EOAI and m-EOAI. There was positive correlation between them and correlation coefficient was 0.46. 
Discussion
Though PPM after AVR is a concern of investigators in congenital cardiac surgery, it is not an area of focus for others. [22] [23] [24] Within the last 10 years, several important articles about PPM after MVR have been published, in which the authors describe PPM after MVR and longterm clinical outcome. [15] [16] [17] [18] [19] [20] [21] The key message of this study was 1) the incidence of PPM after MVR is higher when r-EOAI instead of m-EOAI is used in defining PPM. 2) PPM after MVR was not associated with the MACE, pulmonary hypertension, and survival. 3) The risk factor for PPM after MVR was male gender when r-EOAI was used and bioprosthesis when m-EOAI was used. Results on the effect of PPM after MVR on late cardiac outcomes and long term survival are mixed. Lam et al. reported that the PPM after MVR was associated with recurrence of congestive heart failure and postoperative pulmonary hypertension, and late survival independently 17) Li et al. reported that persistent pulmonary hypertension after MVR was associated with PPM after MVR. 18) Magne et al. reported that severe PPM after MVR, which was defined as EOAI <0.9, was an independent predictor of mortality. 19) All three used measured EOAI to define the PPM, and they concluded that the PPM after MVR has a negative impact on late survival or cardiac outcome.
On the contrary, Jamieson et al. reported that the PPM after MVR was not a predictor of overall mortality of 15 years. They used the referred EOAI to define the PPM. 20) However, they did not consider preoperative and postoperative variables, such as diabetes mellitus, renal failure, chronic obstructive pulmonary disease, and valve pathologies. We had a few similar limitations in our outcome analysis, namely, we inferred the pulmonary arterial pressure using the trans-tricuspid pressure gradient (an index for systemic pulmonary artery pressure). Nevertheless, in agreement with Jamieson et al., the current study showed no negative impact of PPM after MVR on a major adverse cardiac event, pulmonary hypertension, or late survival. We also agree with their conclusion that surgeons should continue to watch for PPM after MVR in their patients. The clinical outcome should be the result of the many factors such as preoperative pulmonary hypertension, bioprosthesis use, and PPM, and we recommend that surgeons maintain a strategy for implanting an adequate size mitral prosthesis to avoid PPM.
As previously described, PPM does occur in patients with AVR. Control of the PPM could contribute towards the reductions in congestive heart failure and regression of left ventricular mass, resulting in improved survival. The indication for surgery for Aortic stenosis is aortic valve area less than 1.0 cm 2 . This indication would be equivalent to the PPM criteria. Similarly the indication for surgery for mitral stenosis is mitral valve area less than 1.5 cm 2 . This would also be the equivalent to the PPM levels. 3) While other studies focused on the impact of PPM on clinical outcome, the present study focused on the characteristics of the PPM patient group. Furthermore, this study revealed that the influence of characteristics on outcomes changed according to whether m-or r-EOAI was used. Whether PPM itself influences the outcome or not, surgeons should prevent PPM after MVR if possible; therefore, risk factor analysis would be beneficial.
Others have used m-EOAI in the continuous equation method to estimate EOA though we used the pressure half time method. Whatever method is used, an actual measurement of EOA is impossible. [25] [26] [27] [28] Of course, the r-EOA is not imperfect. We demonstrated a positive correlation between r-EOAI and m-EOAI, though the patient group was specific for each. Our present study showed that male gender and bioprosthesis are possible risk factors for PPM after MVR. Surgeons can use this information during the preoperative assessment, to avoid PPM after MVR.
Limitation
This is a single-institution, non randomized, retrospective observational clinical study. We used the pressure half time to determine the EOA while others used the continuity equation method. We estimated pulmonary arterial pressure using the trans-tricuspid valve pressure gradient, which would vary depending on the condition of the patient. m-EOAI, measured effective orifice area index; r-EOAI, referred effective orifice area index
